TSHA (Taysha Gene Therapies) EV-to-EBIT : -4.48 (As of May. 13, 2025)

Taysha Gene Therapies EV-to-EBIT Chart

Taysha Gene Therapies Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EV-to-EBIT	Get a 7-Day Free Trial															-2.33	-4.14	-3.00	-14.41	-3.12

Competitive Comparison of Taysha Gene Therapies's EV-to-EBIT

For the Biotechnology subindustry, Taysha Gene Therapies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taysha Gene Therapies's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Taysha Gene Therapies's EV-to-EBIT falls into.

Taysha Gene Therapies EV-to-EBIT Calculation

Taysha Gene Therapies's EV-to-EBIT for today is calculated as:

Taysha Gene Therapies's current Enterprise Value is $399.87 Mil.
Taysha Gene Therapies's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-89.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taysha Gene Therapies  (NAS:TSHA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Taysha Gene Therapies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Taysha Gene Therapies's Enterprise Value for the quarter that ended in Dec. 2024 was $278.70 Mil.
Taysha Gene Therapies's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-89.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taysha Gene Therapies EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Taysha Gene Therapies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Taysha Gene Therapies Business Description